Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Oncology Drug Shortages Persist, but Continue to Evolve

2.

The diamonds that could find cancer

3.

In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?

4.

Gene therapies for BCG-unresponsive bladder cancer have high response rates.

5.

A paper strip test might enable the early detection of cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot